The development of allosteric inverse agonists and neutral antagonists for TSHR is necessary for the treatment of autoimmune hyperthyroidism (Graves’ disease) and associated ophthalmopathy, as well as for the treatment of thyroid cancer caused by activating mutations in TSHR [318,323,326]. Here, TSHR is linked to thyroid gland carcinoma.